On March 19, 2024, Merck & Co., Inc., a global healthcare company based in New Jersey, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC). This registration is part of a shelf registration process, allowing the company to sell shares of its common stock from time to time as part of its Stock Investment Plan. The plan offers a convenient way for participants to purchase Merck's common stock and reinvest cash dividends in additional shares. Participation is open to any registered holder of common stock or any person who becomes a registered holder by enrolling in the plan. The prospectus details the plan's features, including automatic dividend reinvestment, optional cash investments, and full investment of plan funds...Show More

On March 19, 2024, Merck & Co., Inc., a global healthcare company based in New Jersey, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC). This registration is part of a shelf registration process, allowing the company to sell shares of its common stock from time to time as part of its Stock Investment Plan. The plan offers a convenient way for participants to purchase Merck's common stock and reinvest cash dividends in additional shares. Participation is open to any registered holder of common stock or any person who becomes a registered holder by enrolling in the plan. The prospectus details the plan's features, including automatic dividend reinvestment, optional cash investments, and full investment of plan funds. Merck's common stock is listed on the New York Stock Exchange under the symbol 'MRK.' The company intends to use the proceeds from the sale of treasury or new issue common stock for general corporate purposes. The registration statement also includes information on the federal income tax consequences for participants, the plan of distribution, and the legality of the common stock.